drugset / Trial / NCT03258372
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
Non-randomizedCrossoverOpen-labelOther
Summary
This is a Phase 1, single center, fixed sequence, open label, drug-drug interaction study of the effect of multiple doses of rifampin 600 mg daily, a strong CYP3A inducer, on the exposure of mifepristone at 2 dose levels.
Timeline
- Start
- 2017-08-16
- Primary completion
- 2017-11-29
- Completion
- 2017-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mifepristone | Small molecule | 300 mg | — |
| Subject | Mifepristone | Small molecule | 1500 mg | — |
| Subject | Rifampin | Small molecule | 600 mg | — |
Indications
No indication recorded.